GWS
RCKT icon

Glassman Wealth Services’s Rocket Pharmaceuticals RCKT Stock Holding History

Glassman Wealth Services’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-57
Closed -$2K – 1858
2021
Q3 		$2K Buy
57
+55
+2,750% +$2K ﹤0.01% 1210
2021
Q2 		$0 Sell
2
-54
-96% -$2.35K ﹤0.01% 1604
2021
Q1 		$2K Buy
+56
New +$3.08K ﹤0.01% 1127

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Glassman Wealth Services's RCKT Position: Q4 2021 in Review

Glassman Wealth Services sold out of Rocket Pharmaceuticals (RCKT) in Q4 2021, closing a stake of 57 shares — an estimated $2K sold.

Glassman Wealth Services first reported a position in RCKT in Q1 2021 and held it in 3 quarters. The position peaked at $2K in Q3 2021. 148 funds tracked by Wall St. Rank hold RCKT as of Q4 2021.

  • Glassman Wealth Services reported no remaining Rocket Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Glassman Wealth Services sold 57 Rocket Pharmaceuticals shares in Q4 2021, an estimated $2K.
  • Glassman Wealth Services first reported a position in Rocket Pharmaceuticals in Q1 2021 and held it in 3 quarters.
  • Glassman Wealth Services's Rocket Pharmaceuticals position peaked at $2K in Q3 2021.
  • 148 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2021.

Based on Glassman Wealth Services's 13F filing for Q4 2021, filed 14 Feb 2022.